AIP
IMRX icon

Ameritas Investment Partners’s Immuneering IMRX Stock Holding History

Ameritas Investment Partners’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,675
Closed -$4.84K – 3179
2024
Q1 		$4.84K Hold
1,675
– – ﹤0.01% 2954
2023
Q4 		$12.3K Hold
1,675
– – ﹤0.01% 2777
2023
Q3 		$12.9K Hold
1,675
– – ﹤0.01% 2723
2023
Q2 		$17K Buy
+1,675
New +$16.1K ﹤0.01% 2643
2022
Q2 		– Sell
-634
Closed -$4K – 3146
2022
Q1 		$4K Hold
634
– – ﹤0.01% 2995
2021
Q4 		$10K Hold
634
– – ﹤0.01% 2893
2021
Q3 		$17K Buy
+634
New +$17K ﹤0.01% 2773

Other funds holding IMRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ameritas Investment Partners's IMRX Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 1,675 shares — an estimated $4.84K sold.

Ameritas Investment Partners first reported a position in IMRX in Q3 2021 and held it in 7 quarters. The position peaked at $17K in Q3 2021. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

  • Ameritas Investment Partners reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,675 Immuneering shares in Q2 2024, an estimated $4.84K.
  • Ameritas Investment Partners first reported a position in Immuneering in Q3 2021 and held it in 7 quarters.
  • Ameritas Investment Partners's Immuneering position peaked at $17K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.